Biology Reference
In-Depth Information
[25] Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands
CD4+CD25+FoxP3+ regulatory T cells. Blood 2005;105(12):4743-8.
[26] Gatza E, Rogers CE, Clouthier SG, Lowler KP, Tawara I, Liu C, et al. Extracorporeal pho-
topheresis reverses experimental graft-versus-host disease through regulatory T cells.
Blood 2008;112(4):1515-21.
[27] Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical
experience. J Intern Med 2007;262(5):509-25.
[28] Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem
cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II
study. Lancet 2008;371(9624):1579-86.
[29] Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al.
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
Transplantation 2006;81(10):1390-7.
[30] Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, et al. Co-infusion
of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not
reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord
blood transplantation. Bone Marrow Transplant 2011;46(2):200-7.
[31] Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, et al. The correlation between cotrans-
plantation of mesenchymal stem cells and higher recurrence rate in hematologic
malignancy patients: outcome of a pilot clinical study. Leukemia 2008;22(3):593-9.
[32] Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors—development of the
new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol
2005;2(3):150-7.
[33] Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of
an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with
advanced cancer. J Clin Oncol 2005;23(17):3923-31.
[34] Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vori-
nostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist
2007;12(10):1247-52.
[35] Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, et al. Histone
deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC
functions and regulates experimental graft-versus-host disease in mice. J Clin Invest
2008;118(7):2562-73.
[36] Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, et al. Histone deacetylase
inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and
preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 2004;101(11):3921-6.
[37] Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase
inhibition promotes the generation and function of regulatory T cells. Nat Med
2007;13(11):1299-307.
[38] Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al. Natural killer cell-
mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone
deacetylase inhibitor sodium valproate. Cancer Res 2005;65(14):6321-9.
[39] Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells
become susceptible to natural killer cell killing after exposure to histone deacetylase in-
hibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related
chain A and B. Cancer Res 2005;65(23):11136-45.
[40] Choi S, Reddy P. HDAC inhibition and graft versus host disease. Mol Med 2011;17(5-
6):404-16.
[41] Koyama M, Kuns RD, Olver SD, Raffelt NC, Wilson YA, Don AL, et al. Recipient nonhema-
topoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host
disease. Nat Med 2012;18(1):135-42.
[42] Toubai T, Tawara I, Sun Y, Liu C, Nieves E, Evers R, et al. Induction of acute GVHD by
sex-mismatched H-Y antigens in the absence of functional radiosensitive host hemato-
poietic-derived antigen presenting cells. Blood 2011;119:3844-53.
[43] Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, et al. Impact of
in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical
sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Blood 2010;116(16):3080-8.
[44] Mead AJ, Thomson KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G, et al. HLA-
mismatched unrelated donors are a viable alternate graft source for allogeneic trans-
plantation following alemtuzumab-based reduced-intensity conditioning. Blood
2010;115(25):5147-53.
[45] Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R. Long-
term follow-up of myeloablative allogeneic stem cell transplantation using Campath
“in the bag” as T-cell depletion: the Leiden experience. Bone Marrow Transplant
2006;37(12):1129-34.
506
Search WWH ::




Custom Search